Drugs / ALKS 1140
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05019105 Comparator | Oct 2021 → Aug 2022 | central nervous system disorder | Alkermes, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-11 | Alkermes, Inc. | Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders alkermes.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALKS 1140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05019105 ↗ |
| Route | Oral | “administered orally” NCT05019105 ↗ |